Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-04-30

Study Completion Date

2007-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the safety and efficacy of Gleevec (imatinib mesylate) in the treatment of idiopathic pulmonary fibrosis (IPF).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, double-blind, parallel, placebo-controlled, randomized phase 2 study to evaluate the safety and efficacy of Gleevec (imatinib mesylate) in the treatment of Idiopathic Pulmonary Fibrosis (IPF). One-hundred- twenty patients will be enrolled in the trial in total. Subjects must have a diagnosis made by HRCT showing definite or probable IPF and clinical symptoms consistent with IPF with onset between 3 and 36 months prior to screening. Subjects will be randomly assigned to receive either Gleevec 600 mg orally or placebo, once per day for approximately 2 years. The primary efficacy will be progression defined as a greater than 10% decline in the forced vital capacity or death. Measures of safety will include all randomized patients who receive at least one dose of study medication. All adverse events and serious adverse events will be separately tabulated and mapped to a standard classification system and grouped by body system. Any serious adverse events that occur during the trial and 30 days after the end of therapy will be reported to the FDA within 24 hours and followed to outcome.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Pulmonary Fibrosis Lung Disease Pulmonary Fibrosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Pulmonary Fibrosis Respiratory Diseases Interstitial Lung Disease Usual Interstitial Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

ECT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Imatinib Mesylate (Gleevec)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical symptoms consistent with IPF with onset between 3 months and 36 months prior to screening
* Worsening as demonstrated by any one of the following within the past year:

1. \>10% decrease in FVC % of predicted,
2. Worsening chest x-ray or
3. Worsening dyspnea at rest or on exertion
* Age 20 -79 years of age. Subjects aged 20-50 must have diagnosis by either open or video-assisted thoracic surgery (VATS) lung biopsy
* Diagnosis must be made by (HRCT) showing definite or probable IPF AND either of the following:

1. Open or VATS lung biopsy showing definite or probable usual interstitial pneumonitis (UIP)
2. Non-diagnostic transbronchial biopsy to exclude other conditions (including granulomatous disease and malignancies) AND abnormal pulmonary function tests (reduced FVC or decreased DLCO or impaired gas exchange with rest or exercise) AND 2 of the following:



1. Age \>50 years
2. Insidious onset of otherwise unexplained dyspnea or exertion
3. Bibasilar, inspiratory crackles on examination
* FVC\> 55% of predicted value at baseline
* DLCO \> 35% of predicted value at screening
* PaO2 \>60 mmHg (sea level) or 55 mmHg (altitude) at rest on room air
* Able to understand and willing to provide informed consent prior to any study procedures

Exclusion Criteria

* History of clinically significant environmental exposure known to cause pulmonary fibrosis
* Diagnosis of connective tissue disease
* FEV1/FVC ratio \< 0.6 at screening (post-bronchodilator)
* Residual volume \> 120% predicted at screening
* Evidence of active infection
* Any condition other than IPF, which, in the opinion of the site principal investigator, is likely to result in the death of the patient within the next year
* History of unstable or deteriorating cardiac or neurologic disease
* Women with child bearing potential
* Current treatment with corticosteroids, cytoxan, azathioprine, colchicines, pirfenidone, interferon gamma or beta, anti-tumor necrosis factor therapy or with endothelin receptor blockers.

Minimum Eligible Age

20 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Craig E Daniels, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Joseph Lasky, MD

Role: PRINCIPAL_INVESTIGATOR

Tulane University

References

Explore related publications, articles, or registry entries linked to this study.

Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR; Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010 Mar 15;181(6):604-10. doi: 10.1164/rccm.200906-0964OC. Epub 2009 Dec 10.

Reference Type DERIVED

PMID: 20007927 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CST1571E2401

Identifier Type: -

Identifier Source: org_study_id